K Number
K231617
Date Cleared
2023-11-09

(160 days)

Product Code
Regulation Number
892.1000
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

MAGNETOM Free.Max system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head. body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician vield information that may assist in diagnosis.

MAGNETOM Free.Max may also be used for imaging during interventional procedures when performed with MR-compatible devices such as MR Safe biopsy needles.

MAGNETOM Free.Star system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician yield information that may assist in diagnosis.

Device Description

MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA60A include new and modified features compared to the predicate devices MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A (K220575, cleared on June 24, 2022).

Below is a high-level summary of the new and modified hardware and software features compared to the predicate devices MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A:

Hardware
New hardware features:

  • Contour Knee coil
  • Respiratory Sensor

Modified hardware features:

  • myExam 3D Camera
  • Host computer
  • MaRS

Software
New Features and Applications:

  • Injector coupling
  • Respiratory Sensor Support
  • myExam RT Assist (only for MAGNETOM Free.Max)
  • myExam Autopilot Hip
  • Deep Resolve Boost
  • Complex Averaging
  • HASTE_Interactive (only for MAGNETOM Free.Max)
  • BEAT_Interactive (only for MAGNETOM Free.Max)
  • Needle Intervention AddIn (only for MAGNETOM Free.Max)

Modified Features and Applications:

  • Deep Resolve Sharp
  • Deep Resolve Gain
  • SMS Averaging

Other Modifications:

  • Indications for Use (only for MAGNETOM Free.Max)
  • MAGNETOM Free.Max RT Edition marketing bundle (only for MAGNETOM Free.Max)
AI/ML Overview

The provided text describes information about the submission of the MAGNETOM Free.Max and MAGNETOM Free.Star MRI systems for FDA 510(k) clearance, and references a specific AI feature called "Deep Resolve Boost." However, it does not contain acceptance criteria or a detailed study proving the device meets specific performance criteria for the AI feature.

The section titled "Test statistics and test results" for Deep Resolve Boost (Table 1, page 7) mentions that the impact of the network was characterized by quality metrics such as PSNR and SSIM, and visual inspection. It also states: "After successful passing of the quality metrics tests, work-in-progress packages of the network were delivered and evaluated in clinical settings with cooperation partners." This suggests internal testing and evaluation, but does not provide the specific numerical acceptance criteria or the detailed results of these tests.

Therefore, I cannot fully complete the requested table and answer all questions due to the lack of this specific information in the provided document.

However, I can extract the available information regarding the AI feature "Deep Resolve Boost" as much as possible:

1. Table of acceptance criteria and the reported device performance:

Metric / CriteriaAcceptance Criteria (Stated or Implied)Reported Device Performance (Specifics not provided in document)
Deep Resolve Boost
Peak Signal-to-Noise Ratio (PSNR)Must pass initial quality metrics tests.Quantified, but specific numerical values are not reported.
Structural Similarity Index (SSIM)Must pass initial quality metrics tests.Quantified, but specific numerical values are not reported.
Visual Inspection for ArtifactsMust ensure potential artifacts are detected that are not well captured by PSNR/SSIM.Images visually inspected.
Clinical EvaluationMust be evaluated in clinical settings with cooperation partners."work-in-progress packages of the network were delivered and evaluated in clinical settings with cooperation partners." (No specific results or findings reported in this document.)

2. Sample size used for the test set and the data provenance:

  • Test Set (Validation set for AI feature Deep Resolve Boost):
    • Sample Size: 1,874 2D slices.
    • Data Provenance: "in-house measurements and collaboration partners." The document does not specify the country of origin.
    • Retrospective or Prospective: Retrospectively created from ground truth by data manipulation and augmentation.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

  • Number of experts: Not specified.
  • Qualifications of experts: The document states the "acquired datasets represent the ground truth for the training and validation," but it does not specify how this ground truth was established in terms of expert involvement for the test set. It mentions "clinical settings with cooperation partners" for evaluation, but this is distinct from ground truth establishment.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

  • Not specified. The document states "acquired datasets represent the ground truth," suggesting pre-existing data or a different method of ground truth establishment than explicit reader adjudication for this AI feature.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

  • The document states "No clinical tests were conducted to support substantial equivalence for the subject device" (page 10). It mentions that "work-in-progress packages of the network were delivered and evaluated in clinical settings with cooperation partners," but this is not described as an MRMC comparative effectiveness study, nor are any results on human reader improvement reported.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

  • The performance of the "Deep Resolve Boost" AI feature was characterized by "quality metrics such as peak signal-to-noise ratio (PSNR) and structural similarity index (SSIM)" and visual inspection, which suggests a standalone evaluation of the algorithm's output against a reference standard. Specific results are not provided.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

  • For Deep Resolve Boost: "The acquired datasets represent the ground truth for the training and validation." Input data for training was "retrospectively created from the ground truth by data manipulation and augmentation." This implies that high-quality, likely clinical-grade, MRI scans acquired without the AI feature were considered the "ground truth" to which the AI-processed images were compared. It's not explicitly stated if this "ground truth" itself was established by expert consensus, but it infers it from high-quality clinical acquisition.

8. The sample size for the training set:

  • For Deep Resolve Boost: 24,599 2D slices.

9. How the ground truth for the training set was established:

  • "The acquired datasets represent the ground truth for the training and validation. Input data was retrospectively created from the ground truth by data manipulation and augmentation. This process includes further under-sampling of the data by discarding k-space lines, lowering of the SNR level by addition of noise and mirroring of k-space data."
  • This indicates that "ground truth" was established by using full, high-quality MR images. The "input data" for the AI model (which the AI then "boosts") was intentionally degraded (under-sampled, noised) from this high-quality ground truth. The AI's task is to reconstruct the degraded input data back to resemble the original high-quality "ground truth."

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Siemens Medical Solutions USA, Inc. Alina Goodman Regulatory Affairs Professional 40 Liberty Boulevard Malvern, Pennsylvania 19355

November 9, 2023

Re: K231617

Trade/Device Name: MAGNETOM Free.Max; MAGNETOM Free.Star Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic Resonance Diagnostic Device Regulatory Class: Class II Product Code: LNH, MOS Dated: September 11, 2023 Received: September 11, 2023

Dear Alina Goodman:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Julie Sullivan -S

Julie Sullivan, Ph.D. Director DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

{2}------------------------------------------------

Indications for Use

Submission Number (if known)

K231617

Device Name

MAGNETOM Free.Max; MAGNETOM Free.Star

Indications for Use (Describe)

MAGNETOM Free.Max:

MAGNETOM Free.Max system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head. body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician vield information that may assist in diagnosis.

MAGNETOM Free.Max may also be used for imaging during interventional procedures when performed with MR-compatible devices such as MR Safe biopsy needles.

MAGNETOM Free.Star:

MAGNETOM Free.Star system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician yield information that may assist in diagnosis.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act 1990 and 21 CFR క్త 807.92.

1. General Information
Establishment:Siemens Medical Solutions USA, Inc.40 Liberty BoulevardMalvern, PA 19355, USARegistration Number: 2240869
Date Prepared:May 31, 2023
Manufacturer:Siemens Shenzhen Magnetic ResonanceLtd.Siemens MRI Center, Gaoxin C. Ave., 2ndHi-Tech Industrial Park518057 ShenzhenPEOPLE'S REPUBLIC OF CHINARegistration Number: 3004754211
Siemens Healthcare GmbHHenkestrasse 12791052 ErlangenGermanyRegistration Number: 3002808157
2. Contact Information
Alina GoodmanRegulatory Affairs ProfessionalSiemens Medical Solutions USA, Inc.40 Liberty BoulevardMalvern, PA 19355, USAPhone: +1(224)526-1404E-mail: alina.goodman@siemens-healthineers.com
3. Device Name and Classification
Device/ Trade name:MAGNETOM Free.MaxMAGNETOM Free.Star
Classification Name:Magnetic Resonance Diagnostic Device(MRDD)
Classification Panel:Radiology
CFR Code:21 CFR § 892.1000
Classification:II
Product Code:Primary: LNHSecondary: MOS

{4}------------------------------------------------

4. Legally Marketed Predicate Device

4.1 Predicate Device

Trade name: 510(k) Number: Classification Name:

Classification Panel: CFR Code: Classification: Product Code:

Trade name: 510(k) Number: Classification Name:

Classification Panel: CFR Code: Classification: Product Code:

4.2 Reference Device Trade name: 510(k) Number: Classification Name:

Classification Panel: CFR Code: Classification: Product Code:

Trade name: 510(k) Number: Classification Name:

Classification Panel: CFR Code: Classification: Product Code:

Trade name: 510(k) Number: Classification Name:

Classification Panel: CFR Code: Classification:

MAGNETOM Free.Max K220575 Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000 ll Primary: LNH Secondary: MOS

MAGNETOM Free.Star K220575 Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000 Primary: LNH Secondary: MOS

MAGNETOM Sola K221733 Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000 . Primary: LNH Secondary: LNI, MOS

MAGNETOM Amira K223343 Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000 ============================================================================================================================================================================== Primary: LNH Secondary: LNI, MOS

MAGNETOM Vida K213693 Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000

{5}------------------------------------------------

Product Code:

Primary: LNH Secondary: LNI, MOS

5. Indications for Use

MAGNETOM Free.Max:

The indications for use for the subject device MAGNETOM Free.Max with syngo MR XA60A is extended to include MR imaging during interventional procedures compared to the predicate device MAGNETOM Free.Max with syngo MR XA50A:

MAGNETOM Free.Max system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head. body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician vield information that may assist in diagnosis.

MAGNETOM Free.Max may also be used for imaging during interventional procedures when performed with MR-compatible devices such as MR Safe biopsy needles.

MAGNETOM Free.Star:

The indications for use for the subject device MAGNETOM Free.Star with syngo MR XA60A is the same as the predicate device MAGNETOM Free.Star with syngo MR XA50A:

MAGNETOM Free.Star system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross-sectional images that display the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images when interpreted by a trained physician vield information that may assist in diagnosis.

Indications for use modification rationale for MAGNETOM Free.Max:

The product features that support MR imaging during interventional procedures are released in subject device MAGNETOM Free.Max with syngo MR XA60A.

MR imaging during interventional procedures is already included in the reference device MAGNETOM Sola's indications for use and is 510(k) cleared (K221733, cleared on September 13, 2022).

This difference in indications for use does not alter the functionality in assisting diagnosis of the subject device as a magnetic resonance diagnostic device.

Therefore, this difference does not constitute a new intended use according to FDA Guidance "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]".

{6}------------------------------------------------

6. Device Description

MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA60A include new and modified features compared to the predicate devices MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A (K220575, cleared on June 24, 2022).

Below is a high-level summary of the new and modified hardware and software features compared to the predicate devices MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A:

Hardware

New hardware features:

  • Contour Knee coil -
  • -Respiratory Sensor

Modified hardware features:

  • myExam 3D Camera -
  • -Host computer
  • -MaRS

Software

New Features and Applications:

  • -Injector coupling
  • Respiratory Sensor Support -
  • myExam RT Assist (only for MAGNETOM Free.Max) -
  • myExam Autopilot Hip -
  • -Deep Resolve Boost
  • Complex Averaging -
  • HASTE_Interactive (only for MAGNETOM Free.Max) -
  • BEAT_Interactive (only for MAGNETOM Free.Max) -
  • -Needle Intervention AddIn (only for MAGNETOM Free.Max)

Modified Features and Applications:

  • Deep Resolve Sharp -
  • Deep Resolve Gain -
  • -SMS Averaging

Other Modifications:

  • -Indications for Use (only for MAGNETOM Free.Max)
  • MAGNETOM Free.Max RT Edition marketing bundle (only for MAGNETOM -Free.Max)

Below Table 1 shows an executive summary of training and validation dataset of Al feature Deep Resolve Boost in subject devices:

{7}------------------------------------------------

Deep Resolve Boost
Sample size26,473 2D slices
Note: due to reasons of data privacy, we did not record how manyindividuals the datasets belong to. Gender, age and ethnicity distributionwas also not recorded during data collection. Due to the networkarchitecture, attributes like gender, age and ethnicity are not relevant tothe training data.
Sample sourcein-house measurements and collaboration partners
Dataset sliptTraining: 24,599 slices
Validation: 1,874 slices
Note: Data split maintained similar data distribution (e.g. contrast,orientation, field strength, ...) in both training and validation datasets.
Equipments1.5T and 3T MRI scanners [1]
ProtocolsRepresentative protocols (T1, T2 and PD with and withoutfat saturation) which have been altered (e.g. to increaseSNR, increase resolution or reduced acceleration).
Body regionsa broad range of different body regions
ClinicalsubgroupsNo clinical subgroups have been defined for the datasets.
CounfoudersThe input and output variables of the network have beenderived from the same dataset so that no confounders existfor the training methodology.
Test statisticsand testresultsThe impact of the network has been characterized by severalquality metrics such as peak signal-to-noise ratio (PSNR) andstructural similarity index (SSIM). Additionally, images wereinspected visually to ensure that potential artefacts are detectedthat are not well captured by the metrics listed above.After successful passing of the quality metrics tests, work-in-progress packages of the network were delivered and evaluated inclinical settings with cooperation partners.
ReferencestandardThe acquired datasets represent the ground truth for the trainingand validation. Input data was retrospectively created from theground truth by data manipulation and augmentation. This processincludes further under-sampling of the data by discarding k-spacelines, lowering of the SNR level by addition of noise and mirroringof k-space data.

Table 1. Training and validation dataset of Al feature

[1] According to assessment, the network can be transferred to subject devices without the need of retraining with additional data sets.

7. Substantial Equivalence

MAGNETOM Free.Max and MAGNETOM Free.Star with software syngo MR XA60A are substantially equivalent to the predicate devices listed in Table 2:

{8}------------------------------------------------

Predicate DeviceFDA Clearance Numberand DateProductCodeManufacturer
MAGNETOM Free.Maxwith syngo MR XA50AK220575,cleared on June 24, 2022LNH,MOSSiemens ShenzhenMagnetic Resonance Ltd.
MAGNETOM Free.Star withsyngo MR XA50AK220575,cleared on June 24, 2022LNH,MOSSiemens ShenzhenMagnetic Resonance Ltd.
Reference DeviceFDA Clearance Numberand DateProductCodeManufacturer
MAGNETOM Sola withsyngo MR XA51AK221733, cleared onSeptember 13, 2022LNH,LNI,MOSSiemens Healthcare GmbH
MAGNETOM Amira withsyngo MR XA50MK223343, cleared on March23, 2023LNH,LNI,MOSSiemens ShenzhenMagnetic Resonance Ltd.
MAGNETOM Vida withsyngo MR XA50AK213693, cleared onFeburary 25, 2022LNH,LNI,MOSSiemens Healthcare GmbH

Table 2. Predicate devices and reference devices

8. Technological Characteristics

The subject devices, MAGNETOM Free.Max and MAGNETOM Free.Star with software syngo MR XA60A, are substantially equivalent to the predicate devices with reqard to the operational environment, programming language, operating system and performance.

The subject devices conform to the standard for medical device software (IEC 62304) and other relevant IEC and NEMA standards.

There are some differences in technological characteristics between the subject devices and predicate devices, including new and modified hardware and software features, and extended indications for use for MAGNETOM Free.Max. These differences have been tested and the conclusion from the non-clinical data suggests that the features bear an equivalent safety and performance profile to that of the predicate devices.

Please see below Table 3 and Table 4 for the comparison between subject devices and predicate/ reference devices.

Subject DevicesPredicate Devices
HardwareMAGNETOMFree.Max withsoftware syngo MRXA60AMAGNETOMFree.Star withsoftware syngo MRXA60AMAGNETOMFree.Max withError! Referencesource not found.(K220575)MAGNETOMFree.Star withError! Referencesource not found.(K220575)
MagnetSystemYes, same as predicate deviceYes
RF SystemYes, same as predicate deviceYes
Transmissiontechnique -RF Body CoilYes, same as predicate deviceYes
GradientSystemYes, same as predicate deviceYes

Table 3. Hardware Comparison

{9}------------------------------------------------

Patient TableYes, same as predicate deviceYes
ComputerYes, modified compared to predicatedevice:-new host computer hardware-new MaRS hardwareYes
CoilsYes,new coil compared to predicate device:Contour Knee coilYes
Other HWcomponentsYes,Modified compared to predicate device:-myExam 3D CameraNew compared to predicate device:-Respiratory SensorYes

Table 4. Software Features Comparison

Subject DevicesPredicate Devices
SoftwareMAGNETOMFree.Max withsoftware syngo MRXA60AMAGNETOMFree.Star withsoftware syngoMR XA60AMAGNETOMFree.Max withsoftware syngoMR XA50A(K220575)MAGNETOMFree.Star withsyngo MR XA50A(K220575)
Injector couplingYes,new feature migrated from reference deviceMAGNETOM Sola with syngo MR XA51A(K221733)No
Respiratory SensorSupportYes,new feature migrated from reference deviceMAGNETOM Amira with syngo MR XA50M(K223343)No
myExam RT AssistYes,new feature migratedfrom reference deviceMAGNETOM Sola withsyngo MR XA51A(K221733)NoNo
myExam AutoPilotHipYes, new featureNo
Deep ResolveBoostYes,new feature migrated from reference deviceMAGNETOM Vida with syngo MR XA50A(K213693)No
ComplexAveragingYes, new featureNo
HASTE_InteractiveYes,new feature migratedfrom reference deviceMAGNETOM Sola withsyngo MR XA51A(K221733)NoNo
BEAT_InteractiveYes,new feature migratedfrom reference deviceMAGNETOM Sola withsyngo MR XA51A(K221733)NoNo

{10}------------------------------------------------

NeedleIntervention AddInYes, new feature migratedfrom reference deviceMAGNETOM Sola withsyngo MR XA51A(K221733)NoNo
Deep ResolveSharpYes, modified compared to predicatedeviceYes
Deep ResolveGainYes, modified compared to predicatedeviceYes
SMS AveragingYes, modified compared to predicatedeviceYes

9. Nonclinical Tests

The following performance testing was conducted on the subject devices.

Performance TestTested Hardware or SoftwareSource/Rationale for test
Sample clinical imagesNew and modified software features, pulse sequence typesGuidance for Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices
Software verification and validationNew and modified software featuresGuidance for the Content of Premarket Submissions for Software Contained in Medical Devices

The results from each set of tests demonstrate that the devices perform as intended and are thus substantially equivalent to the predicate device to which it has been compared.

10.Clinical Tests / Publications

No clinical tests were conducted to support substantial equivalence for the subject device; however, as stated above, sample clinical images were provided.

11.Safety and Effectiveness

The device labeling contains instructions for use and any necessary cautions and warnings to ensure safe and effective use of the device.

Risk Manaqement is ensured via a risk analysis in compliance with ISO 14971, to identify and provide mitigation of potential hazards early in the design cycle and continuously throughout the development of the product. Siemens adheres to recognized and established industry standards, such as the IEC 60601-1 series, to minimize electrical and mechanical hazards. Furthermore, the devices are intended for healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.

MAGNETOM Free.Max and MAGNETOM Free.Star with software syngo MR XA60A conform to the following FDA recognized and international IEC, ISO and NEMA standards:

{11}------------------------------------------------

RecognitionNumberProductAreaTitle of StandardReferenceNumber and dateStandardsDevelopmentOrganization
19-4General II(ES/EMC)C1:2009/(R)2012 andA2:2010/(R)2012 (ConsolidatedText) Medical electricalequipment - Part 1: Generalrequirements for basic safetyand essential performance (IEC60601-1:2005, MOD)ES60601-1:2005/(R)2012and A1:2012ANSI AAMI
19-36GeneralMedical electrical equipment -Part 1-2: General requirementsfor basic safety and essentialperformance - CollateralStandard: Electromagneticdisturbances - Requirementsand tests60601-1-2:2014 +AMD1:2020IEC
12-295RadiologyMedical electrical equipment -Part 2-33: Particularrequirements for the basicsafety and essentialperformance of magneticresonance equipment formedical diagnosis60601-2-33 Ed. 3.2b:2015IEC
5-125General I(QS/RM)Medical devices - Application ofrisk management to medicaldevices14971 Third Edition2019-12ISO
5-129General I(QS/RM)Medical devices - Part 1:Application of usabilityengineering to medical devices62366-1: 2015 +AMD1:2020ANSI AAMIIEC
13-79Software/InformaticsMedical device software -Software life cycle processes[Including Amendment 1 (2016)]IEC 62304:2006 +AMD1:2015ANSI AAMIIEC
12-232RadiologyAcoustic Noise MeasurementProcedure for DiagnosingMagnetic Resonance ImagingDevicesMS 4-2010NEMA
12-288RadiologyStandards PublicationCharacterization of PhasedArray Coils for DiagnosticMagnetic Resonance ImagesMS 9-2008 (R2014)NEMA
12-342RadiologyDigital Imaging andCommunications in Medicine(DICOM) Set 03/16/2012RadiologyPS 3.1 - 3.20(2021e)NEMA
2-258Biocompatibilitybiological evaluation of medicaldevices - part 1: evaluation andtesting within a riskmanagement process(Biocompatibility)10993-1:2018AAMIANSIISO

12.Conclusion as to Substantial Equivalence

MAGNETOM Free.Max and MAGNETOM Free.Star with software syngo MR XA60A have the same basic technological characteristics as the predicate device systems, MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A (Cleared with K220575 on June 24, 2022), with respect to the magnetic resonance features and functionalities. While there are some differences in technical features compared to the predicate devices, the differences have been tested and the conclusions from

{12}------------------------------------------------

all verification and validation data suggest that the features bear an equivalent safety and performance profile to that of the predicate devices and reference devices.

Siemens believes that MAGNETOM Free.Max and MAGNETOM Free.Star with software syngo MR XA60A are substantially equivalent to the currently marketed device MAGNETOM Free.Max and MAGNETOM Free.Star with syngo MR XA50A.

§ 892.1000 Magnetic resonance diagnostic device.

(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.